Introduction
============

Desflurane has the most rapid onset and offset of action among the volatile anesthetic agents used for general anesthesia, as it has low solubility in blood and body tissues. These properties of desflurane predict rapid induction and recovery from general anesthesia with its use \[[@B1]\]. However, anesthesia induction with desflurane is troublesome because desflurane can cause airway reactivity, tachycardia, and hypertension when inhaled at induction levels with higher concentrations, especially in pediatric patients \[[@B2],[@B3]\].

In pediatric anesthesia, laryngoscopy and tracheal intubation increase the catecholamine level, SBP, and HR temporarily \[[@B4]\]. Such transient change in cardiovascular responses can cause hazardous effects in the patients with pulmonary hypertension, cerebral vascular malformation and increased intracranial pressure \[[@B5],[@B6]\]. Suppression of the cardiovascular responses to desflurane itself as well as to tracheal intubation and airway reactivity are required to adapt the concept of balanced anesthesia during induction with desflurane \[[@B7]\].

Remifentanil is a short acting opioid and is quickly hydrolyzed by nonspecific esterase in the plasma and the multiorgans \[[@B8]\]. The time-to-peak effect of remifentanil is 1.6 min so remifentanil is considered to be effective in the suppression of cardiovascular changes to abrupt stimulation, such as laryngoscopy and tracheal intubation \[[@B9]\]. In addition, there is a study about the optimal dose of remifentanil to minimize cardiovascular changes to tracheal intubation in adults \[[@B10]\].

In pediatric patients, few studies have been performed on the optimal dose of remifentanil during induction of anesthesia, particularly in the case of desflurane anesthesia. Therefore, this study was designed to determine a median effective effect-site concentration (EC~50~) of remifentanil to prevent the cardiovascular changes to tracheal intubation during the 1 MAC desflurane inhalation in pediatric patients. Furthermore, the desflurane related airway reactivity and remifentanil related complications were evaluated in this study.

Materials and Methods
=====================

After the approval of the hospital Institutional Review Board, informed consent was obtained from the patients and the guardians of the patients. American Society of Anesthesiologists (ASA) physical status class I pediatric patients between ages 5-15 years, who were scheduled for elective surgery, were enrolled in this study. The patients\' demographic data are presented in [Table 1](#T1){ref-type="table"}. The patients were excluded if they had a recent history of upper respiratory tract infection, upper airway deformation, anticipated to have difficulty with laryngoscopy, and if tracheal intubation had to be attempted twice or more because of difficult intubation. An aliquot of 5 µg/kg glycopyrrolate was administered intramuscularly as premedication, 30 min before induction of anesthesia.

When the patient arrived into the operating room, we applied standard monitoring such as pulse oximetry, electrocardiography and noninvasive blood pressure. After preoxygenation with 5 L/min of 100% oxygen, 4 mg/kg of thiopental sodium was administered intravenously. At the same time, 1 mg remifentanil was diluted into 50 ml of normal saline (20 µg/ml solution) and was infused by TCI via syringe pump (Pilot Anesthesia 2. Fresenius vial, France) controlled by an Asan pump (2.0.7 version, Bionet Co., Ltd, Seoul, Korea) using the pharmacokinetic model of Minto and colleague \[[@B11]\]. We started to infuse remifentanil at 1 ng/ml and increased the Ce of remifentanil by 1 ng/ml until the concentration reached at target Ce level. As soon as a patient lost consciousness, his or her ventilation was assisted with 5 L/min of 100% oxygen. After the Ce of remifentanil reached the target concentration level, we opened the dial of desflurane vaporizer at 8 vol%.

During the desflurane inhalation, we assessed the signs of desflurane-related airway reactivity (cough, secretion, laryngospasm and bronchospasm) and tachycardia (HR \> 140 beats/min), bradycardia (HR \< 60 beats/min), hypertension (SBP \> 130 mmHg) and hypotension (SBP \< 80 mmHg) for 2 min \[[@B12]\]. Then, 0.2 mg/kg cisatracurium was injected into the patient, and tracheal intubation was performed 2 min later, using a curved laryngoscope. After tracheal intubation, a patient was mechanically ventilated with desflurane 6 vol% and 2 L/min of fresh gas flow with 50% oxygen in air. The ventilator settings were individualized (tidal volume = 8 ml/kg, frequency = 15-25/min). The SBP, diastolic blood pressure (DBP), mean blood pressure (MBP), HR, SpO~2~, end tidal concentrations of carbon dioxide (EtCO~2~) and desflurane (EtDES) were measured at different time points, such as at the time before anesthesia induction (B), when the target effect-site concentration was reached (tCe), 1 min after desflurane inhalation (D1), 2 min after desflurane inhalation (D2), before tracheal intubation (BI), just after tracheal intubation (I0), 1 min after tracheal intubation (I1), and 3 min after tracheal intubation (I3). The rescue regimens were prepared to treat the side effects of remifentanil or desflurane: 0.01 mg/kg atropine for bradycardia and 0.1 mg/kg ephedrine for hypotension.

The EC~50~ of remifentanil for preventing the cardiovascular changes after tracheal intubation was determined by Dixon\'s up-and-down method. We started to infuse the remifentanil at 4 ng/ml, changed the target Ce of remifentanil that was determined with the response of each patient. A success response was defined as changes of HR and SBP at 1 min after tracheal intubation that did not exceed 20% of the figure just before tracheal intubation. If the study appeared to have a successful response, then the Ce of remifentanil was lowered by 1 ng/ml for the next patient but in the opposite, the Ce of remifentanil was increased by 1 ng/ml. A change between consecutive success and failure response was termed a \"crossover\" with a midpoint concentration between the success and failure response concentrations. This study was ended after 8 crossovers had occurred. The 8 crossovers were averaged to find the EC~50~ of remifentanil.

The patients were divided into a success and a failure group according to the response at 1 min after tracheal intubation. The characteristics of patients were compared using the Chi-square test or the t-test. For comparing the repeated measured hemodynamic values between the 2 groups, we used a 2-way repeated measures ANOVA. A probit analysis was used for calculation of EC~50~, EC~95~ (the effect-site concentration of remifentanil for preventing response to particular stimulus in 95% patients), and the confidence interval. The data is presented as means ± SDs. SPSS (version 13. SPSS Inc., Chicago, IL, USA) was used for the statistical analysis; a P value \< 0.05 was considered as statistically significant.

Results
=======

A total of 24 patients were enrolled into this study. The success and failure groups included 12 patients each. There were no significant differences between the success and failure group for gender, age, weight or height.

The EC~50~ of remifentanil to suppress the cardiovascular changes after tracheal intubation in desflurane anesthesia in pediatric patients was calculated as 3.4 ± 0.9 ng/ml from this study ([Fig. 1](#F1){ref-type="fig"}). This value was figured out by averaging the eight crossovers.

The time sequential comparison of the changes in the HR, SBP, DBP, MBP between the success and failure group were presented in [Fig. 2](#F2){ref-type="fig"}. The increase in HR at I0, I3 was significantly less in the success group. The increase of SBP was significantly less in the success group at I0, I1. The increase of DBP, MBP was significantly less in the success group at D2, I0, I1 (P \< 0.05).

In probit analysis, the EC~50~ and EC~95~ of remifentanil were 3.08 ng/ml \[95% confidence interval (CI), 1.8-4.4\] and 5.15 ng/ml \[95% CI, 4.1-16.1\] ([Fig. 3](#F3){ref-type="fig"}).

In the present study, one patient produced hypertension at the point of I0 and a second revealed hypertension at the points of I0, I1 in the failure group. Any complications related to desflurane-associated airway reactivity (cough, secretion, laryngospasm and bronchospasm) were not observed in any patient during the study. None of the side effects of remifentanil (respiratory depression, muscle rigidity, pruritus, shivering, bradycardia, hypotension) occurred during this study.

Discussion
==========

In the past, a high incidence of moderate to severe laryngospasm, coughing, breath holding and secretions were unfavorable side effects that occurred during induction with desflurane in pediatric patients \[[@B3]\]. Opioids may have decreased these side effects; Ahn et al. \[[@B13]\] stated that a continuous remifentanil infusion reduced airway reactivity and stabilized hemodynamics during desflurane inhalation. Lee and Jung \[[@B14]\] stated that the EC~50~ of remifentanil to block the hemodynamic response to tracheal intubation was 3.7 ng/ml during inhalational induction with 1 MAC desflurane in adults. There have been studies on determining the optimal bolus dose of remifentanil to attenuate cardiovascular changes in pediatric patients. Yoon et al. \[[@B15]\] stated that a bolus injection of 2 µg/kg remifentanil was a dosage to attenuate the cardiovascular responses after intubation in pediatric patients. Xue et al. \[[@B16]\] stated that bolus administration of remifentanil 1 or 1.25 µg/kg is effective for attenuation of the cardiovascular intubation response in pediatric patients when anesthesia is induced using 2.5 mg/kg propofol and 0.1 mg/kg vecuronium. In this study, we could demonstrate that the continuous administration of remifentanil was beneficial to stabilize hemodynamic responses and to suppress airway irritation during inhalation induction with desflurane. This study, using Dixon\'s up-and-down method, showed that the EC~50~ of the remifentanil to minimize cardiovascular changes after intubation and when combined with 1 MAC of desflurane in pediatric patients is 3.4 ± 0.9 ng/ml.

We employed cisatracurium as a muscle relaxant for tracheal intubation because of aminosteroidal neuromuscular blocking agents, such as rocuronium and vecuronium that lead directly to pain by activating the C-nociceptor \[[@B17]\]. The pain from rocuronium injection during anesthesia induction may induce brick flexion of the elbow and wrist or generalized movement in particular pediatric patients \[[@B18]\]. Rocuronium injection pain has an effect on cardiovascular changes of increasing HR, blood pressure (BP) and displacement of intravenous catheter that can be harmful to pediatric patients during the induction. Park et al. \[[@B19]\] stated that the EC~50~ of remifentanil for preventing rocuronium injection pain was higher in children than in other age groups. In that research, the EC~50~ of remifentanil for preventing rocuronium induced withdrawal movements was 2.8 ± 0.8 ng/ml in the children\'s group (6-12 yr). If we used rocuronium for tracheal intubation, the HR, BP could be changed at a Ce of 1, 2 ng/ml dose of remifentanil and the result of a success or failure response could be altered as well.

To deliver a stable analgesic concentration of remifentanil, we adapted the TCI device. TCI targeting Ce are more prone to cause complications because they permit an overshoot of the plasma drug concentration to achieve the target Ce rapidly \[[@B20]\]. Lee et al. \[[@B21]\] demonstrated the safety of pretreatment infusion at considerably high concentrations, even at a target Ce of 6 ng/ml (to achieve this target concentration, the plasma concentration of remifentanil reaches about 18 ng/ml). In this study, owing to overshooting of remifentanil could be dangerous in pediatric patients; just in case, we started to administer remifentanil at 1 ng/ml and increased the Ce of remifentanil by 1 ng/ml until the concentration reached at target Ce level. There was no complication related to the high concentration of remifentanil, such as chest wall rigidity, bradycardia, or hypotension.

In the present study, the EC~50~ of remifentanil to minimize the cardiovascular changes due to tracheal intubation was determined by a Dixon\'s up-and-down method. In this method, simulation studies suggest that a sample size including at least 20-40 patients would offer stable estimates of a target dose for most realistic scenarios \[[@B22]\]. A survey of the current use of up-and-down method in anesthesia study showed that most studies use 20 or more patients in a sequential trial; furthermore, some studies were smaller. Statistical methods articles using simulation methods recommend that studies include 20 or more patients. In addition, we calculated EC~50~ in 2 ways statistically, a kind of turning point estimator as nonparametric method, logistic/probit estimator as parametric method. In the turning point estimator, the values of successive assigned dose pairs at which the observed response changed direction (pair reversals) are averaged. This method is commonly used in anesthesia up-and-down method studies \[[@B23]\]. The logistic/probit estimator method was criticized for some biases in accuracy. The parameter estimate of the regression slope is biased and the confidence intervals of the EC~50~ are unrealistically wide. This method adapted ordinarily to the nonindependence of up-and-down data has been developed, but the requirement of tolerance distribution symmetry is necessary \[[@B24]\]. For this reason, Pace and Stylianou \[[@B25]\]. stated that researchers should consider the use of an isotonic regression estimator with confidence intervals derived from boot strapping. It is a well-described variant of restricted least squares regression that constrains the point estimates to be either monotonic increasing or monotonic decreasing \[[@B26]\]. This statistical method may be constant over some range of doses. Thus, we tried to calculate the EC~50~ and EC~95~ by an isotonic regression estimator. The EC~50~ and EC~95~ derived from the isotonic regression estimator are 2.86 ng/ml \[95% CI, 2.08-4.1\] and 4.85 ng/ml \[95% CI, 3.89-4.93\]. Observed and pooled-adjacent-violators algorithm (PAVA) adjusted probability graphs overlap each other, because there were no violations of probability against the dose elevations ([Fig. 4](#F4){ref-type="fig"}). Even though the probit analysis shows a well-defined graph in this study, the confidence intervals of the EC~95~ resulted in unrealistically-wide confidence intervals. The isometric regression estimator was superiority than probit analysis in terms of confidence intervals, as it is calculated from the results of a boot strapping method and shows more acceptable ranges of confidence intervals.

The current study has several limitations. First, volatile induction and maintenance anesthesia (VIMA) may be needed occasionally when a pediatric patient has no intravenous route. So EC~50~ of remifenatnil for suppressing hemodynamic changes during VIMA with desflurane in pediatric patients is critical clinically. Nevertheless, in this study, desflurane inhalation was began after intravenous anesthetics administration on account that pediatric patients are not able to bear the pungency of desflurane in the awake state. Second, there have been few studies that researched the pharmacodynamics and pharmacokinetics of remifentanil in the pediatric patient. For this reason, use of the TCI device is unreliable in pediatric patient. On the other hand, Anderson \[[@B27]\] stated that remifentanil is rapidly cleared by plasma esterase, which is expressed at birth in the pediatric patient in great quantities and its short, unique, context-sensitive half-life is constant, even in small children and neonates. Accordingly, remifentanil doses can be based on pharmacokinetic parameter estimates that were derived from adults. The volume of distribution, central compartment volume, or the elimination half-life of remifentanil remained constant in spite of wide variations in patient age. Third, the ages of the pediatric patients who enrolled in this study varied widely. The age related differences in the remifentanil clearance rate and the volume of distribution could affect the effect site concentration during the study \[[@B28]\]. Moreover, airway reactivity is known to change based on age. Age-related change in bronchial reactivity occurs during childhood, possibly reflecting early changes in airway smooth muscle maturity and later changes in airway wall rigidity \[[@B29]\].

In conclusion, the EC~50~ of remifentanil to minimize the cardiovascular changes to tracheal intubation during 1 MAC desflurane anesthesia was 3.4 ± 0.9 ng/ml by the Turning Point Estimator in pediatric patients. In probit analysis, EC~50~, EC~95~ of remifentanil was 3.08 ng/ml \[95% CI, 1.8-4.4\] and 5.15 ng/ml \[95% CI, 4.1-16.1\]. In pediatric patients, during induction with desflurane combined with remifentanil infusion, there was cardiovascular stability and no airway reactivity.

![Up-and-down sequence. A success response was defined as less than 20% changes in heart rate (HR) and systolic blood pressure (SBP) at 1 min after tracheal intubation compared to those of just before tracheal intubation. If the HR or SBP change exceeded 20%, then it was defined as a failure response. A change between consecutive success and failure responses is a \"crossover\" with a midpoint concentration between the success and failure response concentration. Eight crossovers were averaged to determine the median effective effect-site concentration of remifentanil.](kjae-63-314-g001){#F1}

![Time sequential comparison of the changes in the heart rate (HR), systolic blood pressure (SBP), diastolic blood pressure (DBP), and mean blood pressure (MBP) between the success and failure groups. The success group includes the patients with changes in HR and SBP at 1 min after intubation that did not exceed 20% of the value just before tracheal intubation. If the HR or SBP at 1 min after tracheal intubation exceeded 20% of the value just before tracheal intubation, the particular patient was included in the failure group. S: success group, F: failure group, B: the time before anesthesia induction, tCe: the time when the target effect site concentration was reached, D1: the time 1 min after desflurane inhalation, D2: the time 2 min after desflurane inhalation, BI: the time before tracheal intubation, I0: the time just after tracheal intubation, I1: the time 1 min after tracheal intubation, I3: the time 3 min after tracheal intubation. ^\*^P \< 0.05 compared with the BI value, ^†^P \< 0.05 compared with the failure group.](kjae-63-314-g002){#F2}

![The effect-site concentration and response curves of remifentanil from probit analysis. EC~50~ is 3.08 ng/ml (95% confidence interval, 1.8-4.4). EC~95~ is 5.15 ng/ml (95% confidence interval, 4.1-16.1). EC: Effect-site concentration.](kjae-63-314-g003){#F3}

![Observed and pooled-adjacent-violators algorithm (PAVA) adjusted probability in each concentration. The x-axis are the effect-site concentration of remifentanil. The estimate of the observed probability (solid line, open round) and the PAVA adjusted probability (solid line, solid triangle) at the effect-site concentration of remifentanil are plotted on the y-axis. Observed and PAVA adjusted probability graphs have overlapped each other because there were no violations of probability against the dose elevations.](kjae-63-314-g004){#F4}
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Characteristics of Patients
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Values are presented as mean ± SD or number of patients, as appropriate. A success response was defined as less than 20% changes in heart rate (HR) and systolic blood pressure (SBP) at 1 min after intubation compared to those of just prior to tracheal intubation. A failure response was defined as changes in HR or SBP at 1 min after tracheal intubation that did not exceed 20% of the values just before tracheal intubation. M: male, F: female, Airway reactivity: cough, secretion, laryngospasm, and bronchospasm.
